Tevogen Bio expands AI in immunotherapy development

WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a biopharmaceutical company, has announced the expansion of its artificial intelligence initiative, Tevogen.AI™. The program is designed to enhance the company’s ExacTcell™ technology, which is central to its development of innovative immunotherapies. By integrating machine learning and predictive modeling, Tevogen.AI aims to improve target identification and pre-clinical processes, potentially accelerating clinical timelines and reducing development costs.

Tevogen.AI has developed two proprietary technologies, PredicTcell™ and AdapTcell™, both with patents pending. PredicTcell is an AI tool that predicts interactions between peptide complexes and T cell receptors, which could refine immunotherapy treatments. AdapTcell decodes interactions between human leukocyte antigens (HLA) and T cells, potentially opening new therapeutic avenues.

The company’s AI-driven platforms are supported by a terabyte-scale database that processes millions of protein and peptide interactions across various diseases and the human genome. These platforms are expected to aid in clinical trial patient identification, driving efficiency and targeted results.

To accommodate the growth of its AI division, Tevogen is expanding its headquarters to include facilities for a team of data scientists and engineers. In a statement, Tevogen CEO Dr. Ryan Saadi noted the potential impact of Tevogen.AI across multiple healthcare sectors.

Strategic partnerships with Microsoft (NASDAQ:MSFT), which provides AI expertise, cloud computing infrastructure, and scientific resources, and Databricks, which offers specialized data engineering and analytics capabilities, are set to accelerate drug discovery processes within Tevogen’s AI initiative. Microsoft, currently trading near its 52-week high with a robust revenue growth of 14.13% over the last twelve months, brings considerable technological expertise to this partnership. According to InvestingPro analysis, Microsoft maintains a "GREAT" financial health score, with 25 analysts recently revising their earnings estimates upward for the upcoming period.

While the company is optimistic about the potential of Tevogen.AI to transform healthcare, these forward-looking statements are subject to risks and uncertainties, including the need for additional capital, regulatory changes, and technological developments.

Tevogen reaffirms its commitment to transparent communication with stockholders and plans to continue providing updates on the progress and achievements of Tevogen.AI. The information presented in this news article is based on a press release statement from Tevogen Bio Inc.

In other recent news, Nvidia is drawing significant attention as its shares surged in premarket trading, outperforming its peers in the Magnificent Seven group. This increase comes ahead of Nvidia’s anticipated earnings report, which investors are closely watching. Meanwhile, Microsoft remains in focus as Jefferies, a global investment firm, maintained its stock rating and price target for the company, signaling a stable outlook. This decision reflects Jefferies’ current assessment of Microsoft’s market position and future prospects.

OpenAI is making headlines with its plan to transition into a public-benefit corporation, aiming for a $300 billion valuation. This restructuring could pave the way for a potential Initial Public Offering (IPO) in the future, although the company emphasizes that such a move would depend on market conditions and its own readiness. The conversion process involves securing approvals from both the Delaware and California Attorneys General. Tesla and other major tech companies experienced a dip in premarket trading due to uncertainties around tariff policies, with Tesla’s shares specifically dropping by 1.2%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.